Skip to main content

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Publication ,  Journal Article
Zelenetz, AD; Gordon, LI; Abramson, JS; Advani, RH; Bartlett, NL; Caimi, PF; Chang, JE; Chavez, JC; Christian, B; Fayad, LE; Glenn, MJ ...
Published in: J Natl Compr Canc Netw
June 1, 2019

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 1, 2019

Volume

17

Issue

6

Start / End Page

650 / 661

Location

United States

Related Subject Headings

  • United States
  • Signal Transduction
  • Receptors, Chimeric Antigen
  • Phosphoinositide-3 Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Recurrence, Local
  • Medical Oncology
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., … Sundar, H. (2019). NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw, 17(6), 650–661. https://doi.org/10.6004/jnccn.2019.0029
Zelenetz, Andrew D., Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, et al. “NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.J Natl Compr Canc Netw 17, no. 6 (June 1, 2019): 650–61. https://doi.org/10.6004/jnccn.2019.0029.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019 Jun 1;17(6):650–61.
Zelenetz, Andrew D., et al. “NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.J Natl Compr Canc Netw, vol. 17, no. 6, June 2019, pp. 650–61. Pubmed, doi:10.6004/jnccn.2019.0029.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019 Jun 1;17(6):650–661.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 1, 2019

Volume

17

Issue

6

Start / End Page

650 / 661

Location

United States

Related Subject Headings

  • United States
  • Signal Transduction
  • Receptors, Chimeric Antigen
  • Phosphoinositide-3 Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Recurrence, Local
  • Medical Oncology
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular